Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Non-Current Assets: 2017-2024

Historic Non-Current Assets for Cidara Therapeutics (CDTX) over the last 8 years, with Dec 2024 value amounting to $4.1 million.

  • Cidara Therapeutics' Non-Current Assets rose 1263.83% to $75.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $75.8 million, marking a year-over-year increase of 1263.83%. This contributed to the annual value of $4.1 million for FY2024, which is 34.27% down from last year.
  • Cidara Therapeutics' Non-Current Assets amounted to $4.1 million in FY2024, which was down 34.27% from $6.2 million recorded in FY2023.
  • Cidara Therapeutics' 5-year Non-Current Assets high stood at $6.2 million for FY2023, and its period low was $2.4 million during FY2022.
  • Over the past 3 years, Cidara Therapeutics' median Non-Current Assets value was $4.1 million (recorded in 2024), while the average stood at $4.2 million.
  • Per our database at Business Quant, Cidara Therapeutics' Non-Current Assets soared by 158.04% in 2023 and then crashed by 34.27% in 2024.
  • Yearly analysis of 5 years shows Cidara Therapeutics' Non-Current Assets stood at $3.2 million in 2020, then climbed by 12.19% to $3.6 million in 2021, then plummeted by 34.02% to $2.4 million in 2022, then spiked by 158.04% to $6.2 million in 2023, then plummeted by 34.27% to $4.1 million in 2024.